SynVaccine

Design and Construction of Viral-based Products

Health Tech & Life Sciences
Active
Seed Tel Aviv-Yafo, Israel Founded 2013
Website ↗
Last updated 2026-06-18
Total raised
$1.8M
Last: 2017-11
Stage
Seed
Founded
2013
Headcount
6
HQ
Tel Aviv-Yafo, Israel
Sector
Health Tech & Life Sciences

About

SynVaccine has developed a CAD/CAM platform for designing and fabricating designer viruses for biotechnology. The company utilizes a multidisciplinary approach combining technologies, such as synthetic biology, virology, bio-informatics, engineering, and robotics, to make viruses that can be used to develop new vaccines. SynVaccine's technology enables the design and fabrication of viral genomes using a safety-focused design approach. The resulting viruses have the potential to overcome the limitations of those found in nature or developed through traditional technologies. SynVaccine was founded as part of Rad BioMed, an Israel-based evergreen family fund that invests in early-stage biomedical start-ups, and on the basis of commercialized research from Tel Aviv University and Weizmann Institute of Science led by Professor Tamir Tuller.

Funding history · 2 rounds · $1.8M total

Q&A

What is SynVaccine's primary focus?
SynVaccine specializes in the design and construction of viral-based products, utilizing a CAD/CAM platform to create designer viruses for biotechnology applications, particularly in vaccine development.
When was SynVaccine founded?
SynVaccine was founded in July 2013.
How many employees does SynVaccine currently have?
SynVaccine has 1-10 employees.
What is SynVaccine's total funding to date?
SynVaccine has raised a total of $1,756,000 USD.
Which investors participated in SynVaccine's November 2017 funding round?
In November 2017, SynVaccine received funding from A2Z Venture Partners and Pix Vine Capital.
What type of funding did SynVaccine receive in June 2017?
In June 2017, SynVaccine received a Grant from EU Horizon 2020.
Who are the co-founders of SynVaccine?
SynVaccine was co-founded by Tamir Tuller and Tuval Ben Yehezkel.
What is the primary sector for SynVaccine?
SynVaccine's primary sector is Health Tech & Life Sciences.

Team · 2

Founder · Co-Founder & CSO
LinkedIn ↗
Founder · Co-founder (No longer with the company)
LinkedIn ↗

Sectors & technology

Primary sector
Health Tech & Life Sciences
Sub-sectors
Health Tech & Life SciencesPharma & Medical BiotechnologyDrugs Discovery & Development
Technologies
Biologicals
Target customers
Healthcare & Life SciencesLife SciencesPharmaceuticalsBiotechnology
Business model
B2B

Highlights

1 Patents

Tags

pharmaceuticalsviral-diseasesbioinformaticsvaccines-developmentdisease-managementgenomicsanimal-healthlaboratoriesvaccinesbioconvergence
Full data — links, identifiers, deals & radar signals (jobs, patents, research, more)

External links

Websitesynvaccine.com

Identifiers & details

Founded2013-7
Employees (exact)6

Radar intelligence

Patents

EPO4

Publications (Crossref)

Works3

Web history (Wayback)

Domainsynvaccine.com

Certificate / subdomain footprint

Subdomains2